- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Novavax Inc (NVAX)
Novavax Inc stock price live, this page displays NASDAQ NVAX stock exchange data. View the NVAX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Novavax Inc real time stock price chart below.
What Is the Novavax Inc Stock Price Today?
The Novavax Inc stock price today is 7.580.
What Is the Stock Symbol for Novavax Inc?
The stock symbol for Novavax Inc is ""NVAX.""
What Stock Exchange Does Novavax Inc Trade On?
Novavax Inc is listed and trades on the NASDAQ stock exchange.
Is Novavax Inc a Good Stock to Buy?
Determining whether Novavax Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NVAX quote. (ISIN: US6700024010)
What Is the Novavax Inc Stock Price Today?
The Novavax Inc stock price today is 7.580.
What Is the Stock Symbol for Novavax Inc?
The stock symbol for Novavax Inc is ""NVAX.""
What Stock Exchange Does Novavax Inc Trade On?
Novavax Inc is listed and trades on the NASDAQ stock exchange.
Is Novavax Inc a Good Stock to Buy?
Determining whether Novavax Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NVAX quote. (ISIN: US6700024010)
Fair Value
An estimate of a Novavax's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.425
7.790
52 wk Range
5.010
15.220
NVAX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NVAX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Novavax's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.4257.790
52 wk Range
5.01015.220
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NVAX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Novavax's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
12.857
Upside
+69.62%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral
Novavax Inc Company Profile
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax Inc Earnings Call Summary for Q2/2025
- Novavax reported Q2 2025 net income of $107M ($0.62/share), beating forecasts. Revenue reached $239M, surpassing expectations by 53%.
- Stock surged 18.17% pre-market to $7.17. Company maintains strong profitability metrics with P/E ratio of 2.26 and revenue growth of 25.92%.
- R&D and SG&A costs reduced by 41%. Cash and receivables over $850M at quarter-end. Full-year revenue guidance raised to $1.0-1.05B.
- CEO emphasized focus on strategic partnerships and innovation. CFO highlighted commitment to financial discipline and operational efficiency.
- Company targets non-GAAP profitability by 2027, expects additional milestone payments from Sanofi. Projected 2025 R&D and SG&A: $495-545M.
Last Updated: 06/08/2025, 15:10
Read Full TranscriptCompare NVAX to Peers and Sector
Metrics to compare | NVAX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNVAXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 2.9x | −3.3x | −0.6x | |
PEG Ratio | 0.01 | −0.20 | 0.00 | |
Price/Book | 32.7x | 1.1x | 2.6x | |
Price / LTM Sales | 1.1x | 7.9x | 3.3x | |
Upside (Analyst Target) | 5.5% | 78.4% | 39.1% | |
Fair Value Upside | Unlock | 7.9% | 5.4% | Unlock |
Analyst Ratings
3 Buy
1 Hold
3 Sell
Ratings:
7 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 12.857
(+69.62% Upside)
Earnings
Latest Release
Aug 06, 2025
EPS / Forecast
0.62 / -0.06
Revenue / Forecast
239.00M / 156.23M
People Also Watch
FAQ
What Stock Exchange Does Novavax Trade On?
Novavax is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Novavax?
The stock symbol for Novavax is "NVAX."
What Is the Novavax Market Cap?
As of today, Novavax market cap is 1.23B.
What Is Novavax's Earnings Per Share (TTM)?
The Novavax EPS (TTM) is 2.63.
When Is the Next Novavax Earnings Date?
Novavax will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is NVAX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Novavax Stock Split?
Novavax has split 1 times.
How Many Employees Does Novavax Have?
Novavax has 952 employees.
What is the current trading status of Novavax (NVAX)?
As of 29 Aug 2025, Novavax (NVAX) is trading at a price of 7.580, with a previous close of 7.58. The stock has fluctuated within a day range of 7.425 to 7.790, while its 52-week range spans from 5.010 to 15.220.
What Is Novavax (NVAX) Price Target According to Analysts?
The average 12-month price target for Novavax is USD12.85714, with a high estimate of USD25 and a low estimate of USD6. 3 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Neutral. The stock has an +69.62% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.